Taysha Gene Therapies Stock Performance
| TSHA Stock | USD 1.52 0.01 0.65% |
The entity has a beta of 0.13, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Taysha Gene's returns are expected to increase less than the market. However, during the bear market, the loss of holding Taysha Gene is expected to be smaller as well. At this point, Taysha Gene Therapies has a negative expected return of -0.0875%. Please make sure to validate Taysha Gene's potential upside, day median price, and the relationship between the total risk alpha and accumulation distribution , to decide if Taysha Gene Therapies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Taysha Gene Therapies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical indicators, Taysha Gene is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/13/2024 |
2 | Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursdays Pre-Market Session | 11/14/2024 |
3 | Taysha Gene Therapies Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags | 11/15/2024 |
4 | Taysha Gene Therapies Trading Up 13.8 percent - Heres What Happened - MarketBeat | 11/22/2024 |
5 | Taysha Gene Therapies SWOT analysis stock poised for growth in Rett syndrome market | 11/26/2024 |
6 | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 12/06/2024 |
7 | Fmr LLC Has 37.54 Million Stake in Taysha Gene Therapies, Inc. - MarketBeat | 12/09/2024 |
8 | Acquisition by Alam Kamran of 149900 shares of Taysha Gene at 1.18 subject to Rule 16b-3 | 12/13/2024 |
9 | Why Did Taysha Gene Therapies Stock Drop Below Its Moving Average | 12/20/2024 |
10 | Acquisition by Alam Kamran of 431000 shares of Taysha Gene at 1.85 subject to Rule 16b-3 | 01/02/2025 |
| Begin Period Cash Flow | 90.5 M |
Taysha |
Taysha Gene Relative Risk vs. Return Landscape
If you would invest 197.00 in Taysha Gene Therapies on October 27, 2024 and sell it today you would lose (45.00) from holding Taysha Gene Therapies or give up 22.84% of portfolio value over 90 days. Taysha Gene Therapies is currently does not generate positive expected returns and assumes 8.8456% risk (volatility on return distribution) over the 90 days horizon. In different words, 78% of stocks are less volatile than Taysha, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Taysha Gene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Taysha Gene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Taysha Gene Therapies, and traders can use it to determine the average amount a Taysha Gene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0099
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TSHA |
Estimated Market Risk
| 8.85 actual daily | 78 78% of assets are less volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Taysha Gene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Taysha Gene by adding Taysha Gene to a well-diversified portfolio.
Taysha Gene Fundamentals Growth
Taysha Stock prices reflect investors' perceptions of the future prospects and financial health of Taysha Gene, and Taysha Gene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Taysha Stock performance.
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (11.78) % | ||||
| Current Valuation | 218.41 M | ||||
| Shares Outstanding | 204.94 M | ||||
| Price To Book | 3.53 X | ||||
| Price To Sales | 31.42 X | ||||
| Revenue | 15.45 M | ||||
| Gross Profit | 9.91 M | ||||
| EBITDA | (105.2 M) | ||||
| Net Income | (111.57 M) | ||||
| Cash And Equivalents | 66.24 M | ||||
| Cash Per Share | 1.61 X | ||||
| Total Debt | 61.11 M | ||||
| Debt To Equity | 1.93 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (73.02 M) | ||||
| Earnings Per Share | 0.63 X | ||||
| Market Capitalization | 311.51 M | ||||
| Total Asset | 172.73 M | ||||
| Retained Earnings | (513.01 M) | ||||
| Working Capital | 113.11 M | ||||
About Taysha Gene Performance
By analyzing Taysha Gene's fundamental ratios, stakeholders can gain valuable insights into Taysha Gene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Taysha Gene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Taysha Gene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.61) | (0.58) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.71) | (1.80) |
Things to note about Taysha Gene Therapies performance evaluation
Checking the ongoing alerts about Taysha Gene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Taysha Gene Therapies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Taysha Gene generated a negative expected return over the last 90 days | |
| Taysha Gene has high historical volatility and very poor performance | |
| Taysha Gene may become a speculative penny stock | |
| Taysha Gene has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.45 M. Net Loss for the year was (111.57 M) with profit before overhead, payroll, taxes, and interest of 9.91 M. | |
| Taysha Gene Therapies currently holds about 66.24 M in cash with (73.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Taysha Gene has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 |
- Analyzing Taysha Gene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Taysha Gene's stock is overvalued or undervalued compared to its peers.
- Examining Taysha Gene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Taysha Gene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Taysha Gene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Taysha Gene's stock. These opinions can provide insight into Taysha Gene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Taysha Stock analysis
When running Taysha Gene's price analysis, check to measure Taysha Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taysha Gene is operating at the current time. Most of Taysha Gene's value examination focuses on studying past and present price action to predict the probability of Taysha Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taysha Gene's price. Additionally, you may evaluate how the addition of Taysha Gene to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |